The year 2016 has been both intensive and exciting and during which Xintela has experienced strong growth. Together with our current progress in regenerative medicine and cancer, we have also strengthened the company’s structure and resources. We conducted an oversubscribed rights issue and listed the company on Nasdaq First North, in addition to making several recruitments within the clinical development, business development and commercialisation functions.
We plan a more extensive update in January on the company’s milestones in the different development projects, including the on-going equine study that focuses on determining whether our stem cells are safe to use. Once again, we visited the group at Cornell University, Ithaca, New York, and confirmed that the analyses from the study are on their way to completion and which we can report on soon.
In this newsletter we continue our film interview series, this time with Xintela’s well respected Board Member, Karin Wingstrand. We also report on interesting external scientific data that support our own research into cancer. Happy reading in December darkness!
Evy Lundgren-Åkerlund
CEO, Xintela AB.
